Zim Laboratories Ltd
ZIMLABZim Laboratories Ltd's price has outrun its earnings. +5.5% in a year against EPS −56.4% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +5.5% in a year while annual EPS moved −56.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (9 weeks in) while the P/E sits at the 100th percentile of its own 7-year range. Underneath, the last four quarters read deteriorating — profit −23.4% year on year, and 306% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Zim Laboratories Ltd trades at ₹125, in a confirmed uptrend and 9 weeks into that stage. That is +37.2% against its own 200-day average. It sits at 96% of a 52-week range of ₹64 to ₹128. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks.
Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹125 it trades +37.2% versus its 200-day average and sits at 96% of its 52-week range (₹64–₹128).
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 100th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Zim Laboratories Ltd trades at 149.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 28.9×, measured across 7.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 149.0× is about the priciest it has ever traded, against a long-run median of 28.9× measured over 7.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −56.4% against a +5.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +20.8%/yr price move, ~−9.1%/yr came from earnings growth and ~+29.9 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Zim Laboratories Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue and profit growth are shrinking (revenue growth −3.2% latest (single-quarter readings) against +21.3% at its 12-quarter best), ROCE slipping at 5.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −1.3% | −2.1% | +4.0% | +3.4% |
| Profit | −50.0% | −37.0% | −3.0% | +1.8% |
| EPS | −56.4% | −39.9% | −6.2% | — |
| Share price | +5.5% | +3.1% | +20.8% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
41.2/100 — rank 32 of 43 in Pharma - Formulators · 76% evidence confidence
Zim Laboratories Ltd scores 41.2 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 32. Price leads the evidence: RS versus the benchmark is 50.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 6.2 + 7.2 + 8.7 + 19.1 = 41.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Zim Laboratories Ltd reported ₹105 Cr of revenue in the Mar 26 quarter, −3.2% year on year. Over 10 years it has compounded at 3.4% a year. The last full year, FY26, came in at ₹374 Cr. The last four reported quarters add to ₹374 Cr.
Zim Laboratories Ltd reported ₹105 Cr of revenue in the Mar 26 quarter, −3.2% year on year. Over 10 years it has compounded at 3.4% a year. The last full year, FY26, came in at ₹374 Cr. The last four reported quarters add to ₹374 Cr.
FY26 revenue came in at ₹374 Cr (−1.3% on the year), capping 10 years at 3.4% compound. The latest quarter (Mar 26) printed ₹105 Cr, −3.2% year on year.
Pace check: the last four quarters averaged −1.6% growth against the decade's 3.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −1.2% over the last 4 quarters against +0.9%/yr over the last 8 — stabilising; TTM profit −51.9% vs −41.8%/yr — rolling over.
→ Revenue slipped — did margins hold as it scaled? Next: 6.8% this quarter (−6.6 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Zim Laboratories Ltd's operating margin is 6.8% in the Mar 26 quarter, −6.6 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −4.0% to 13.0%. The current quarter sits inside that band.
Zim Laboratories Ltd's operating margin is 6.8% in the Mar 26 quarter, −6.6 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −4.0% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 6.8%, −6.6 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −4.0%–13.0%.
🚨 Why the margin moved: operating margin went −6.6 pp year on year while gross margin went −0.4 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit −23.4% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Zim Laboratories Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, −23.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The 10-year compound rate is 1.8%. That is 3.6% of the quarter's revenue. The same quarter a year earlier earned ₹4.9 Cr. 2 of the last 12 reported quarters were loss-making.
Zim Laboratories Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, −23.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The 10-year compound rate is 1.8%. That is 3.6% of the quarter's revenue. The same quarter a year earlier earned ₹4.9 Cr. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹3.7 Cr, −23.4% year on year. On the full year, FY26 printed ₹6.0 Cr (−50.0%), and the 10-year compound rate is 1.8%.
🚨 Why profit moved: revenue contributed −3.2% and the margin −6.6 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −109.7% vs revenue −1.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 306% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 306% of Zim Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹50.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹44.0 Cr of capital spending, ₹6.0 Cr was left as free cash.
FY26: operating cash of ₹50.0 Cr against reported profit of ₹6.0 Cr, leaving free cash of ₹6.0 Cr after ₹44.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 306% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 306%: the cash cycle stretched 90 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 3.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹178 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Zim Laboratories Ltd's cash conversion cycle runs 152 days in FY26, up from 62 days in FY21. Capital spending ran ₹178 Cr over the last 3 years. At FY26 sales of ₹374 Cr each day of that cycle holds about ₹1.0 Cr, so roughly ₹156 Cr sits inside the business at any moment.
FY26: debtors at 106 days, inventory at 207 days — roughly 6.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 152 days, looser than FY21's 62.
The full loop: cash goes out to suppliers and production on day 0; stock waits 207 days to sell; customers pay about 106 days after that; and suppliers themselves are paid at 161 days — netting out to the 152-day cycle.
In money terms: at FY26 sales of ₹374 Cr, each day of the cycle holds about ₹1.0 Cr — so the 152-day loop keeps roughly ₹156 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹178 Cr over the last 3 fiscal years against ₹56.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹96.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 5% and the ROIC − WACC spread is −10.1 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Zim Laboratories Ltd earns a ROCE of 5% in FY26. That is up from a trough of 5% in FY20. Return on invested capital clears the cost of that capital by −10.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.6% net margin on 0.69× asset turns.
FY26 ROCE is 5%, recovered from a FY20 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 1.6% net margin × 0.69× asset turns × 1.81× balance-sheet leverage ≈ 2.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 1.9% − 12.0% = a −10.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.43.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Zim Laboratories Ltd carries total debt of ₹127 Cr against shareholder equity of ₹296 Cr as of Mar 26, a debt-to-equity of 0.43. On the annual view that ratio went from 0.30 in FY22 to 0.43 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹127 Cr against shareholder equity of ₹296 Cr — a debt-to-equity of 0.43. On the annual view, debt-to-equity went from 0.30 (FY22) to 0.43 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 2.9 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 2.9 points of Zim Laboratories Ltd over 8 quarters, the biggest move on the register. That takes promoters to 30.4% of the company. Domestic institutions moved +1.3 points over the same window, to 1.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −2.9 points over 8 quarters to 30.4%; Domestic institutions: +1.3 points over 8 quarters to 1.3%; Foreign institutions: +0.0 points over 8 quarters to 0.0%.
🚨 Why the register moved: promoters drove it (−2.9 points), absorbed on the other side by domestic institutions (+1.3 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Zim Laboratories Ltd: the Z-score reads 2.39. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.39 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.39.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Zim Laboratories Ltd this page | 149.0× | ₹646 Cr | Deteriorating | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read |
Frequently asked questions
What is Zim Laboratories Ltd's share price today?
Zim Laboratories Ltd trades at ₹125, +5.5% over the past year. The company is valued at ₹646 Cr. The stock sits at 96% of its 52-week range of ₹64–₹128, +37.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 9 weeks in. — as of 24 July 2026.
What were Zim Laboratories Ltd's latest quarterly results?
Zim Laboratories Ltd reported revenue of ₹105 Cr and net profit of ₹3.7 Cr for the Mar 26 quarter. Revenue fell 3.2% and profit fell 23.4% year on year. Earnings per share were ₹0.70. The operating margin was 6.8%, 6.6 pp lower than a year earlier. — as of 24 July 2026.
What is Zim Laboratories Ltd's revenue?
Zim Laboratories Ltd reported revenue of ₹105 Cr in the Mar 26 quarter, −3.2% year on year. For the full FY26 fiscal year, revenue was ₹374 Cr (−1.3%). Over the last 10 years revenue compounded at 3.4% a year. — as of 24 July 2026.
What is Zim Laboratories Ltd's profit?
Zim Laboratories Ltd earned ₹3.7 Cr of net profit in the Mar 26 quarter, −23.4% year on year. Full-year FY26 profit was ₹6.0 Cr. The operating margin ran 6.8% in the latest quarter. — as of 24 July 2026.
What is Zim Laboratories Ltd's market cap?
Zim Laboratories Ltd's market capitalisation is ₹646 Cr at a share price of ₹125. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Zim Laboratories Ltd's P/E ratio?
Zim Laboratories Ltd trades at a P/E of 149.0×, at the 100th percentile of its own 7-year range, against a long-run median of 28.9×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Zim Laboratories Ltd pay a dividend?
Not in its latest year — Zim Laboratories Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 12 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Zim Laboratories Ltd overvalued?
On its own history, Zim Laboratories Ltd looks expensive against its own history: its P/E of 149.0× sits at the 100th percentile of its 7-year range (long-run median 28.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Zim Laboratories Ltd growing?
Not right now — Zim Laboratories Ltd's latest numbers are shrinking: latest-quarter revenue −3.2% year on year, profit −23.4%, and the margin −6.6 pp at 6.8%. The 10-year compound rates are 3.4% (revenue) and 1.8% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Zim Laboratories Ltd performing?
Zim Laboratories Ltd is in a confirmed uptrend, 9 weeks in. Its latest quarter's revenue fell 3.2% and profit fell 23.4% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 19 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Zim Laboratories Ltd in?
Deteriorating — revenue and profit growth are shrinking (revenue growth −3.2% latest (single-quarter readings) against +21.3% at its 12-quarter best), ROCE slipping at 5.0%. The read comes from the last 12 quarters of growth (revenue growth −3.2% latest, profit growth −23.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Zim Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 9 of stage 2), trading +37.2% versus its 200-day average and at 96% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Zim Laboratories Ltd beating the market?
On recent form, yes — Zim Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks, the same metric the week-by-week ribbon on this page draws. — as of 24 July 2026.
Will Zim Laboratories Ltd's share price go up?
This page publishes no price forecast for Zim Laboratories Ltd. What it measures instead: the share price is ₹125, the price is in a confirmed uptrend 9 weeks in. Its P/E of 149.0× sits at the 100th percentile of its own 7-year range. — as of 24 July 2026.
Who owns Zim Laboratories Ltd?
Promoters hold 30.4% of Zim Laboratories Ltd, foreign institutions 0.0%, domestic institutions 1.3% and the public 68.3% (latest quarter). The biggest move on the register over the last two years: Promoters cut 2.9 points over 8 quarters. — as of 24 July 2026.
Does Zim Laboratories Ltd have too much debt?
It is moderate — Zim Laboratories Ltd's debt-to-equity is 0.43, and operating profit covers the interest bill 2×. FY26 borrowings were ₹127 Cr against equity of ₹297 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Zim Laboratories Ltd's capex?
Zim Laboratories Ltd spent ₹178 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹44.0 Cr, with ₹96.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Zim Laboratories Ltd's cash flow?
Zim Laboratories Ltd generated ₹50.0 Cr of operating cash flow in FY26 and ₹6.0 Cr of free cash flow after ₹44.0 Cr of capital spending. Reported profit that year was ₹6.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Zim Laboratories Ltd's profit real cash?
Yes — over the last 3 fiscal years, 306% of Zim Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹50.0 Cr against reported profit of ₹6.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Zim Laboratories Ltd?
On the balance sheet, the Z-score reads 2.39 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 24 July 2026.
Where is Zim Laboratories Ltd in its business cycle?
Zim Laboratories Ltd's FY26 operating margin was 8.0%, against a 12-year band of −4.0%–13.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 6.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Zim Laboratories Ltd story?
The sharpest disagreement: the price moved +5.5% in a year while annual EPS moved −56.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Zim Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Zim Laboratories Ltd's price has outrun its earnings. +5.5% in a year against EPS −56.4% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.